Latest news and press releases about AC Immune S.A. (ACIU): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
AC Immune S.A. is a biotech firm operating at the clinical stage, dedicated to pioneering, formulating, and advancing therapeutic agents and diagnostic tools. Its core mission is addressing neurodegenerative conditions rooted in protein misfolding, both preventatively and therapeutically.
Price
| Price | $2.65 |
| Market Cap | $270M |
| Exchange | NASDAQ |
| Country | CH |
Valuation Ratios
| Price / Book | 6.42 |
| EV / EBITDA | -5.05 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -99.17% |
| Return on Invested Capital | -86.61% |
| Return on Assets | -28.70% |
| Gross Margin | 100.00% |
| Operating Margin | -252.25% |
| Net Margin | -246.49% |
Related companies: ALDX · AMRN · ANNX · ANRO · CLLS · CTNM · DRTS
Explore sector: Healthcare · Biotechnology
More sections of ACIU: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks